Martin van Eijk

Martin van Eijk

Auto-generated profile, based on publicly available information

Martin van Eijk

Division of Molecular Host Defence, Department of Infectious Diseases and Immunology, Faculty of Veterinary Medicine, Utrecht University, 3512 Utrecht, The Netherlands

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 February 2013 in Journal of Innate Immunity
Verified
Journal Article
Open access
PDF file
MHMarine L.B. Hillaire
Marine L.B. Hillaire
HHHenk P. Haagsman
Henk P. Haagsman
AOAlbert D.M.E. Osterhaus
Albert D.M.E. Osterhaus
GRGuus F. Rimmelzwaan
Guus F. Rimmelzwaan
MEMartin van Eijk
Martin van Eijk
Influenza A viruses (IAV) cause respiratory tract infections annually associated with excess mortality and morbidity. Nonspecific, innate immune mechanisms play a key role in protection against viral invasion at early stages of infection. A soluble protein present in mucosal secretions of the lung, surfactant protein D (SP-D), is an important component of this initial barrier that helps to prevent and limit IAV infections of the respiratory epithelium. This collagenous C-type lectin binds IAVs and thereby inhibits attachment and entry of the virus but also contributes to enhanced clearance of SP-D-opsonized virus via interactions with phagocytic cells. In addition, SP-D modulates the inflammatory response and helps to maintain a balance between effective neutralization/killing of IAV, and protection against alveolar damage resulting from IAV-induced excessive inflammatory responses. The mechanisms of interaction between SP-D and IAV not only depend on the structure and binding properties of SP-D but also on strain-specific features of IAV, and both issues will be discussed. SP-D from pigs exhibits distinct anti-IAV properties and is discussed in more detail. Finally, the potential of SP-D as a prophylactic and/or therapeutic antiviral agent to protect humans against infections by IAV is discussed.

1 December 1995 in Analytical Biochemistry
Verified
Journal Article
Closed access
MEMartin van Eijk
Martin van Eijk
CHCatharina G.M.De Haas
Catharina G.M.De Haas
HHHenk P. Haagsman
Henk P. Haagsman

1 June 2011 in Journal of Biological Chemistry
Verified
Journal Article
Open access
MEMartin van Eijk
Martin van Eijk
LBLaurie Bruinsma
Laurie Bruinsma
KHKevan Hartshorn
Kevan Hartshorn
MWMitchell R. White
Mitchell R. White
MRMichael J. Rynkiewicz
Michael J. Rynkiewicz
HHHenk P. Haagsman
Henk P. Haagsman
Porcine surfactant protein D (pSP-D) displays distinctively strong, broad-range inhibitory activity against influenza A virus (IAV). N-Linked glycosylation of the carbohydrate recognition domain (CRD) of pSP-D contributes to the high affinity of this collectin for IAV. To investigate the role of the N-linked glycan further, HEK293E protein expression was used to produce recombinant pSP-D (RpSP-D) that has similar structural and antiviral properties as NpSP-D. We introduced an additional N-linked glycan in the CRD of RpSP-D but this modification did not alter the antiviral activity. Human SP-D is unglycosylated in its CRD and less active against IAV compared with pSP-D. In an attempt to modify its antiviral properties, several recombinant human SP-D (RhSP-D) mutants were constructed with N-linked glycans introduced at various locations within its CRD. To retain lectin activity, necessary for the primary interactions between SP-D and IAV, N-linked glycosylation of RhSP-D was shown to be restricted to the corresponding position in the CRD of either pSP-D or surfactant protein A (SP-A). These N-glycosylated RhSP-D mutants, however, did not show increased neutralization activity against IAV. By developing RhSP-D mutants that also have the pSP-D-specific Ser-Gly-Ala loop inserted in the CRD, we could demonstrate that the N-linked glycan-mediated interactions between pSP-D and IAV involves additional structural prerequisites of the pSP-D CRD. Ultimately, these studies will help to develop highly effective SP-D-based therapeutic and prophylactic drugs against IAV.

1 July 2018 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
MEMartin van Eijk
Martin van Eijk
MRMichael J. Rynkiewicz
Michael J. Rynkiewicz
KKKshitij Khatri
Kshitij Khatri
NLNancy Leymarie
Nancy Leymarie
JZJoseph Zaia
Joseph Zaia
HHHenk P. Haagsman
Henk P. Haagsman
Innate immunity is critical in the early containment of influenza A virus (IAV) infection, and surfactant protein D (SP-D) plays a crucial role in the pulmonary defense against IAV. In pigs, which are important intermediate hosts during the generation of pandemic IAVs, SP-D uses its unique carbohydrate recognition domain (CRD) to interact with IAV. An N-linked CRD glycosylation provides interactions with the sialic acid–binding site of IAV, and a tripeptide loop at the lectin-binding site facilitates enhanced interactions with IAV glycans. Here, to investigate both mechanisms of IAV neutralization in greater detail, we produced an N-glycosylated neck-CRD fragment of porcine SP-D (RpNCRD) in HEK293 cells. X-ray crystallography disclosed that the N-glycan did not alter the CRD backbone structure, including the lectin site conformation, but revealed a potential second nonlectin-binding site for glycans. IAV hemagglutination inhibition, IAV aggregation, and neutralization of IAV infection studies showed that RpNCRD, unlike the human analogue RhNCRD, exhibits potent neutralizing activity against pandemic A/Aichi/68 (H3N2), enabled by both porcine-specific structural features of its CRD. MS analysis revealed an N-glycan site-occupancy of >98% at Asn-303 of RpNCRD with complex-type, heterogeneously branched and predominantly α(2,3)-sialylated oligosaccharides. Glycan-binding array data characterized both RpNCRD and RhNCRD as mannose-type lectins. RpNCRD also bound LewisY structures, whereas RhNCRD bound polylactosamine-containing glycans. The presence of the N-glycan in the CRD increases the glycan-binding specificity of RpNCRD. These insights increase our understanding of porcine-specific innate defense against pandemic IAV and may inform the design of recombinant SP-D–based antiviral drugs.

26 December 2018 in Viruses
Verified
Journal Article
Open access
PDF file
AFAnne-Laure Favier
Anne-Laure Favier
Olivier ReynardOlivier Reynard
Olivier Reynard
EGEvelyne Gout
Evelyne Gout
MEMartin van Eijk
Martin van Eijk
HHHenk Haagsman
Henk Haagsman
NTNicole Thielens
Nicole Thielens
Since the largest 2014–2016 Ebola virus disease outbreak in West Africa, understanding of Ebola virus infection has improved, notably the involvement of innate immune mediators. Amongst them, collectins are important players in the antiviral innate immune defense. A screening of Ebola glycoprotein (GP)-collectins interactions revealed the specific interaction of human surfactant protein D (hSP-D), a lectin expressed in lung and liver, two compartments where Ebola was found in vivo. Further analyses have demonstrated an involvement of hSP-D in the enhancement of virus infection in several in vitro models. Similar effects were observed for porcine SP-D (pSP-D). In addition, both hSP-D and pSP-D interacted with Reston virus (RESTV) GP and enhanced pseudoviral infection in pulmonary cells. Thus, our study reveals a novel partner of Ebola GP that may participate to enhance viral spread.

1 December 2003
Verified
Journal Article
Closed access
HHH P Haagsman
H P Haagsman
VHV Herias
V Herias
MEM Van Eijk
M Van Eijk